Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | MET | P08581 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14784145 | 0.96 | HTR3A (0.49) | HTR3ACHRM1DRD2DRD3DRD4 | |
| SCHEMBL14783729 | 0.90 | HTR3A (0.45) | HTR3ACHRM1DRD2DRD3DRD4 | |
| SCHEMBL14783571 | 0.87 | AKR1C3 (0.43) | HTR3ACHRM1DRD2DRD3DRD4 | |
| SCHEMBL12470515 | 0.86 | MET (0.45) | METCA1CA2PDE3BPDE3A | |
| SCHEMBL14783372 | 0.85 | MET (0.41) | HTR3ACHRM1DRD2DRD3DRD4 | |
| SCHEMBL14784591 | 0.85 | MET (0.44) | HTR3ACHRM1DRD2DRD3DRD4 | |
| SCHEMBL12470775 | 0.84 | CNR1 (0.42) | HTR3ACHRM1DRD2DRD3DRD4 | |
| SCHEMBL15259187 | 0.84 | MET (0.49) | METPDE3BPDE3AMEN1KMT2A | |
| SCHEMBL14783557 | 0.83 | AKR1C3 (0.41) | DRD2DRD3METCA1CA2 | |
| SCHEMBL14783178 | 0.83 | PDE3B (0.43) | CHRM1DRD2DRD3DRD4MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| EP-2755976-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4]TRIAZOLO [4, 3 -A]PYRADINES AS TYROSINE KINASE | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2673277-A1 | [1, 2, 4]TRIAZOLO [4, 3 -B]PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | Novartis AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| US-20130324526-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2013-12-05 | — | — | US | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012107500-A1 | [1, 2, 4] TRIAZOLO [4, 3 -B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | NOVARTIS AG (CH) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250799-A1 | Triazolopyridine Compounds | FLT3, RET, MET | HTR3A 1291/4885CHRM1 1033/4885DRD2 1981/4885 |
| US-20130245002-A1 | Triazolopyridine Compounds | FLT3, RET, MET | HTR3A 1291/4885CHRM1 1033/4885DRD2 1981/4885 |
| US-20130324526-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE | MET, ERBB2, RET | HTR3A 782/4885CHRM1 1512/4885DRD2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.